Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 12, 2012, Pages 1142-1153

  Yamane, Keiichiro ^a   Ikeda, Tomoyuki ^a   Taniguchi, Ryoji ^a   Watanabe, Shin ^a   Kawato, Mitsunori ^a   Kondo, Hirokazu ^a   Shirakawa, Ryutaro ^a,b   Higashi, Tomohito ^a   Toma, Masanao ^a   Tabuchi, Arata ^a   Tamura, Toshihiro ^a   Takahashi, Kanako ^a   Watanabe, Haruyo ^a   Yoshikawa, Yuka ^a   Kita, Toru ^a,c   Kimura, Takeshi ^a   Horiuchi, Hisanori ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Antiplatelet therapy; Aspirin; Aspirin low responder; Bleeding; Clinical outcome

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLATELET REACTIVITY; RETROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

AGED; ASPIRIN; BLOOD PLATELETS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871806093     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14100     Document Type: Article

References (39)

1. Horiuchi H: Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems. Ann Med, 2006; 38: 162-172
2. Antiplatelet Trialists' Collaboration: Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86
3. King SB, 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW: 2007 Focused Update of the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation, 2008; 117: 261-295
4. Morimoto T, Nakayama M, Saito Y, Ogawa H: Aspirin for primary prevention of atherosclerotic disease in Japan. J Atheroscler Thromb, 2007; 14: 159-166
5. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ, 1994; 308: 81-106
6. Tantry US, Bliden KP, Gurbel PA: Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother, 2005; 6: 2027-2045
7. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet, 2006; 367: 606-617
8. Ikeda T, Taniguchi R, Watanabe S, Kawato M, Kondo H, Shirakawa R, Yamane K, Toma M, Tamura T, Takahashi K, Watanabe H, Yoshikawa Y, Tabuchi A, Kita T, Kimura T, Horiuchi H: Characterization of the Antiplatelet Effect of Aspirin at Enrollment and After 2-Year Follow-up in a Real Clinical Setting in Japan. Circ J, 2010; 74: 1227-1235
9. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 2008; 336: 195-198
10. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol, 2004; 43: 1122-1126
11. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002; 105: 1650-1655
12. Bruno A, McConnell JP, Cohen SN, Tietjen GE, Wallis RA, Gorelick PB, Bang NU: Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke, 2004; 35: 727-730
13. Atiemo AD, Ng'Alla LS, Vaidya D, Williams MS: Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis, 2008; 25: 173-178
14. Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R: Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2007; 99: 1518-1522
15. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y: Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost, 2006; 4: 1271-1278
16. Toyoda K: Pharmacotherapy for the secondary prevention of stroke. Drugs, 2009; 69: 633-647
17. Lanas A, Wu P, Medin J, Mills EJ: Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol, 2011; 9: 762-768 e766
18. Kawai T, Yamagishi T, Goto S: Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period. J Atheroscler Thromb, 2009; 16: 155-163
19. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009; 373: 1849-1860
20. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K: Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke, 2008; 39: 1740-1745
21. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet, 2004; 364: 331-337
22. Tabuchi A, Taniguchi R, Takahashi K, Kondo H, Kawato M, Morimoto T, Kimura T, Kita T, Horiuchi H: Action of aspirin on whole blood-aggregation evaluated by the screen filtration pressure method. Circ J, 2008; 72: 420-426
23. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 2003; 41: 961-965
24. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, Akyuz U, Unal Dai S, Narin A: The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol, 2007; 23: 201-206
25. Frelinger AL, 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD: Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation, 2009; 120: 2586-2596
26. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med, 2007; 120: 631-635
27. Stejskal D, Vaclavik J, Lacnak B, Proskova J: Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med, 2006; 17: 349-354
28. Beigel R, Hod H, Fefer P, Asher E, Novikov I, Shenkman B, Savion N, Varon D, Matetzky S: Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol, 2011; 107: 339-342
29. Dotevall G, Ekenved G: The absorption of acetylsalicylic acid from the stomach in relation to intragastric pH. Scand J Gastroenterol, 1976; 11: 801-805
30. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 2008; 118: 1894-1909
31. Giraud MN, Sanduja SK, Felder TB, Illich PA, Dial EJ, Lichtenberger LM: Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther, 1997; 11: 899-906
32. Wurtz M, Grove EL, Kristensen SD, Hvas AM: The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart, 2010; 96: 368-371
33. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, Lindhardsen J, Madsen JK, Kober L, Torp-Pedersen C, Gislason GH: Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ, 2011; 342: d2690
34. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol, 2010; 9: 959-968
35. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y: Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008; 300: 2134-2141
36. Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke, 2005; 36: 1588-1593
37. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H: Warfarin, aspirin, or both after myocardial infarction. N Engl J Med, 2002; 347: 969-974
38. Ohkuma H, Fujita S, Suzuki S: Incidence of aneurysmal subarachnoid hemorrhage in Shimokita, Japan, from 1989 to 1998. Stroke, 2002; 33: 195-199
39. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M: Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol, 2011; 57: 2474-2483